

TRIKAFTA (COPACKAGED) - (100MG,75MG,50MG;150MG, 50MG,37.5MG,25MG;75MG ; Tablet)

| | | | |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR | Innovator | Vertex pharma |
| Dosage | 100MG,75MG,50MG;150MG, 50MG,37.5MG,25MG;75MG ; Tablet | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

TRIKAFTA (COPACKAGED) - (80MG, 60MG, 40MG;59.5MG ; Granules)

| | | | |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR | Innovator | Vertex pharma |
| Dosage | 80MG, 60MG, 40MG;59.5MG ; Granules | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

TRIKAFTA (COPACKAGED) - (100MG, 75MG, 50MG;75MG ; Granules)

| | | | |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR | Innovator | Vertex pharma |
| Dosage | 100MG, 75MG, 50MG;75MG ; Granules | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.